Last reviewed · How we verify
NovoLog/NovoRapid
NovoLog/NovoRapid is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels.
NovoLog/NovoRapid is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels. Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | NovoLog/NovoRapid |
|---|---|
| Also known as | Insulin aspart |
| Sponsor | Sanofi |
| Drug class | rapid-acting insulin analog |
| Target | insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating glucose uptake in cells, inhibiting glucose production in the liver, and promoting the storage of glucose in muscles and fat cells. This results in a decrease in blood glucose levels. NovoLog/NovoRapid is administered via subcutaneous injection and has a rapid onset of action, making it suitable for mealtime glucose control.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NovoLog/NovoRapid CI brief — competitive landscape report
- NovoLog/NovoRapid updates RSS · CI watch RSS
- Sanofi portfolio CI